New Jersey-based Seeger Weiss has been named Litigation Department of the Year in the Products Liability and Mass Torts category at the New Jersey Law Journal’s 2026 New Jersey Legal Awards. Winners were announced on October 29, 2026, at The Palace at Somerset Park in Somerset, New Jersey.
Over the past year, the department took on key leadership roles in some of the country’s largest mass tort litigations and helped bring two of them, among others, to resolution. In July 2026, founding partner Christopher A. Seeger, serving as Plaintiffs’ Lead Negotiation Counsel in the Johnson & Johnson Talcum Powder Litigation, helped secure an uncapped global settlement that ends more than a decade of litigation. Under the agreement, J&J will pay at least $5.8 billion to resolve the claims of about 70,000 plaintiffs in the MDL and related state court proceedings, all women who developed ovarian cancer after using Johnson & Johnson’s Baby Powder, Shower to Shower, and other talc-based products.
In June 2026, Seeger, serving as lead counsel in the Depo-Provera Products Liability Litigation, a role he was appointed to in March 2025, reached an agreement with Pfizer that gives eligible plaintiffs in the multidistrict litigation the opportunity to resolve their claims that the contraceptive injection caused meningioma brain tumors. Two other Seeger Weiss attorneys also hold leadership roles in the litigation. Senior partner David Buchanan chairs the Trial Subcommittee and serves on the ESI and Discovery Subcommittee and partner Caleb Seeley serves on the Plaintiffs’ Steering Committee.
Covering New Jersey’s legal community since 1878, the New Jersey Law Journal reports on the state’s courts, law firms, and legal industry. Its annual New Jersey Legal Awards honor outstanding achievement by New Jersey attorneys and law firms. Law Journal editors and an outside judging panel select the honorees.
The selection methodology can be found here.
No aspect of this or any advertisement has been approved by the Supreme Court of New Jersey.
Prior results do not guarantee or predict a similar outcome in any future matter.